Welcome to our dedicated page for Vita Coco Company SEC filings (Ticker: COCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vita Coco Company, Inc. (NASDAQ: COCO) files reports and disclosures with the U.S. Securities and Exchange Commission as part of its obligations as a public company. This page compiles those SEC filings and pairs them with AI-powered tools that help explain the information contained in key documents.
Through its filings, the company reports on topics such as quarterly and annual financial performance, business developments, and regulatory matters. Recent Form 8-K filings, for example, reference press releases announcing financial results for quarters ended June 30 and September 30, 2025, as well as a company statement regarding tariff relief affecting coconut water products. These filings provide detail on net sales, gross profit, net income, and non-GAAP measures like Adjusted EBITDA, along with management’s commentary on factors such as tariffs, costs, and demand for Vita Coco Coconut Water and related products.
On this page, users can access core documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K as they become available through EDGAR. AI-generated summaries are designed to highlight major themes, clarify technical language, and surface items that may matter to shareholders, such as segment performance, tariff discussions, or capital allocation programs mentioned in earnings releases.
In addition, this page provides convenient access to insider transaction reports on Form 4 and other ownership-related filings when they are filed. Together, these resources allow investors, analysts, and interested readers to review The Vita Coco Company’s regulatory disclosures in one place, with AI assistance to make complex filings easier to understand.
Vita Coco Company, Inc. Chief Commercial Officer Charles van Es reported an open-market sale of 2,000 shares of common stock on April 1, 2026 at $48.67 per share. The sale was effected under a Rule 10b5-1 trading plan.
Following this sale, he directly owns 77,691 shares of common stock. He also holds multiple non-qualified stock options to buy Vita Coco common stock, with exercise prices ranging from $10.178 to $33.36 per share and expiration dates between 2030 and 2035.
COCO filed a Form 144 proposing the sale of 2,000 shares of Common Stock.
The shares are described as resulting from Restricted Stock Vesting with a vesting date of 11/27/2024. The excerpt also shows a prior reported sale on 03/16/2026 by Charles Van Es of 2,000 shares for $115,960.00.
Vita Coco Co Inc Schedule 13G/A amendment shows The Vanguard Group reporting zero beneficial ownership of Vita Coco common stock. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately pursuant to SEC Release No. 34-39538. The filing is signed by Ashley Grim on 03/27/2026.
Vita Coco Company, Inc. Chief Financial Officer Corey Baker reported an open‑market sale of 2,000 shares of common stock on March 19, 2026 at an average price of $55.45 per share. The sale was executed under a Rule 10b5‑1 trading plan, indicating it was pre‑scheduled rather than a discretionary trade.
After this transaction, Baker directly holds 25,951 common shares. He also holds several non‑qualified stock options to acquire additional Vita Coco common shares, with exercise prices ranging from $16.91 to $33.36 and expiration dates between 2033 and 2035.
Vita Coco Company, Inc.’s Chief Financial Officer Corey Baker reported open-market sales of company common stock. On March 17, 2026, he sold 2,000 shares at $59.92 per share, followed by another 2,000 shares at $58.04 per share on March 18, 2026, for total reported sales of 4,000 shares.
After these transactions, Baker directly holds 27,951 shares of common stock. He also holds multiple non-qualified stock options to purchase additional common shares with exercise prices ranging from $16.91 to $33.36. The filing notes that the stock sales were carried out under a Rule 10b5-1 trading plan, indicating they were pre-arranged.
Vita Coco Company, Inc. director Kenneth Sadowsky reported an open-market sale of 3,900 shares of common stock at a weighted average price of $56.918 per share. The trade was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.
After the sale, Sadowsky directly holds 590,466 shares of common stock. He also holds a fully vested, currently exercisable non-qualified stock option to buy 27,300 shares of common stock at an exercise price of $10.178 per share, expiring on January 2, 2030.
COCO filed a Form 144 reporting multiple sales of Common Stock. The filing lists four separate sales of 2,000 shares each on 03/13/2026, 03/16/2026, 03/17/2026, and 03/18/2026 with proceeds listed for each sale.
The filing also lists securities tied to restricted stock vesting dated 03/10/2025 (185 shares) and 03/10/2026 (1,815 shares) under compensation disclosures.
Vita Coco Company, Inc. Chief Operating Officer Jonathan Burth exercised options for 40,000 shares of common stock at an exercise price of $10.178 per share and sold 60,000 shares in open-market transactions on March 16, 2026 at prices ranging from $57.98 to $60.00. The sales were effected under a Rule 10b5-1 trading plan.
Following these transactions, Burth holds 57,910 shares of common stock directly. He also retains multiple option awards, including non-qualified stock options exercisable for 40,950 underlying shares at an exercise price of $10.178 per share expiring on February 10, 2030, along with additional options at higher exercise prices and later expiration dates.
Vita Coco Company, Inc. Chief Commercial Officer Charles van Es reported an open-market sale of 2,000 shares of common stock at $57.98 per share on March 16, 2026. The filing notes these sales were effected under a Rule 10b5-1 trading plan.
After the transaction, van Es directly holds 79,691 shares of common stock. He also holds several non-qualified stock options to buy additional Vita Coco shares, including grants exercisable at $10.178 per share expiring on February 10, 2030 and January 11, 2031, and higher-priced options expiring through March 4, 2035.
COCO reported insider sales of common stock by Corey Baker. The filing lists three dispositions of 2,000 shares each on 03/13/2026, 03/16/2026 and 03/17/2026 with reported proceeds of $117,720, $115,960 and $119,840 respectively. The form also records a prior grant/vesting of 2,000 shares (restricted stock vesting) dated 03/10/2025.